Sunshine Biopharma, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $9.26 million, a slight decrease of 1.6% from $9.41 million in the same period last year. For the first half of 2026, the company generated $17.35 million in revenue, down 5.2% from $18.31 million in the first half of 2025. The decline in revenue is attributed to the termination of distribution agreements effective December 31, 2025, which impacted sales. The cost of sales increased to $6.84 million for the second quarter, resulting in a gross profit of $2.43 million, compared to $3.42 million in the prior year.

The company reported a net loss of $1.56 million for the second quarter of 2026, or $1.15 per share, an improvement from a net loss of $1.77 million, or $3.94 per share, in the same quarter of 2025. For the six-month period, the net loss was $2.81 million, or $2.95 per share, compared to a loss of $2.95 million, or $8.19 per share, in the prior year. The reduction in losses is attributed to a decrease in general and administrative expenses, which fell to $4.04 million in the second quarter from $5.48 million in the previous year, primarily due to lower consulting and research and development costs.

In terms of operational developments, Sunshine Biopharma continues to focus on its proprietary drug development programs, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections. The company has also expanded its product pipeline, with 12 additional drugs expected to launch in 2026, which will enhance its presence in the Canadian generic drug market, valued at approximately $11.2 billion annually. As of June 30, 2026, the company had cash and cash equivalents of $13.75 million, reflecting a significant increase from $9.12 million at the end of 2025.

The company’s total assets increased to $33.63 million as of June 30, 2026, up from $30.08 million at the end of 2025, while total liabilities decreased to $6.09 million from $7.04 million. Sunshine Biopharma's shareholders' equity rose to $27.54 million, compared to $23.04 million at the end of the previous fiscal year. The company has indicated that it expects its existing cash reserves, along with cash generated from sales, to be sufficient to fund operations for the next 27 months, although it anticipates needing to raise additional capital for future expansion and research initiatives.

Looking ahead, Sunshine Biopharma aims to streamline operations and increase sales to improve profitability. The company is actively pursuing opportunities to expand its market share in Canada and potentially other regions, while continuing to develop its proprietary drug candidates. The management remains focused on navigating the challenges posed by market conditions and regulatory environments to achieve its strategic objectives.

About Sunshine Biopharma, Inc

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing generic, OTC, and proprietary medicines across therapeutic areas such as oncology and antivirals. It owns a portfolio of approved generics in Canada, develops novel drug candidates including mRNA-based cancer therapies and coronavirus inhibitors, and seeks to expand its market presence through licensing, licensing agreements, and strategic partnerships. The company emphasizes innovation, regulatory compliance, and competitive positioning in global markets.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov